TheraVet starts the distribution of its line of bone substitutes BIOCERA-VET® in Italy with Alcyon Italia. Italy, with 10 million dogs and 8.7 million cats, represents the fourth largest market for companions in Europe. The Company started the assessment and entry into this market from May 2023 with the build-up of a KoLs network and the start of multiple clinical trials assessing BIOCERA-VET® Bone Surgery RTU in unmet medical need indications: the clinical assessment of BIOCERA-VET® in revision surgery of distal radioulnar fracture (DRUF) in toy and miniature breed started in May 2023 and for which the recruitment phase is now completed and the clinical assessment of BIOCERA-VET® in septic and aseptic non-union in all breeds, recruitment phase is ongoing.

Thanks to the endorsement and support of Italian key opinion leaders, the distribution of the full line of BIOCERA-VET® starts in collaboration with Alcyon Italia, leader in the distribution in Italy for orthopedics. Alcyon Italia will be in charge of the active promotion of the 13 BIOCERA-VET® references to veterinarians through educational program (webinar, orthopedic courses), online platform, Italian conferences (SCIVAC, UNISVET, SIOVET, SITOV?) supported by the technical expertise developed in house.